Françoise Brunner‐Ferber

766 total citations
29 papers, 629 citations indexed

About

Françoise Brunner‐Ferber is a scholar working on Cardiology and Cardiovascular Medicine, Ophthalmology and Molecular Biology. According to data from OpenAlex, Françoise Brunner‐Ferber has authored 29 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 6 papers in Ophthalmology and 5 papers in Molecular Biology. Recurrent topics in Françoise Brunner‐Ferber's work include Heart Failure Treatment and Management (6 papers), Glaucoma and retinal disorders (5 papers) and Neuropeptides and Animal Physiology (4 papers). Françoise Brunner‐Ferber is often cited by papers focused on Heart Failure Treatment and Management (6 papers), Glaucoma and retinal disorders (5 papers) and Neuropeptides and Animal Physiology (4 papers). Françoise Brunner‐Ferber collaborates with scholars based in Switzerland, United States and France. Françoise Brunner‐Ferber's co-authors include Jérôme Biollaz, Héctor W. Gómez, J. Nussberger, Bernard Waeber, Thierry Buclin, Hans R. Brunner, Christian van Delden, Bruno François, Jean-Claude Péchère and Thilo Köhler and has published in prestigious journals such as Scientific Reports, Kidney International and Hypertension.

In The Last Decade

Françoise Brunner‐Ferber

28 papers receiving 594 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Françoise Brunner‐Ferber Switzerland 13 210 194 101 80 74 29 629
Danyal Imani Iran 17 173 0.8× 44 0.2× 96 1.0× 51 0.6× 59 0.8× 40 719
Tetsuro Matsuura Japan 14 195 0.9× 28 0.1× 56 0.6× 29 0.4× 17 0.2× 63 670
Lori Mixson United States 15 191 0.9× 98 0.5× 136 1.3× 24 0.3× 69 0.9× 26 700
Subhadip Choudhuri India 17 172 0.8× 54 0.3× 41 0.4× 19 0.2× 49 0.7× 32 742
Mehmet Namuslu Türkiye 16 75 0.4× 39 0.2× 68 0.7× 59 0.7× 75 1.0× 40 559
Nedret Kılıç Türkiye 14 138 0.7× 31 0.2× 43 0.4× 45 0.6× 15 0.2× 32 519
Theo Nell South Africa 17 223 1.1× 71 0.4× 78 0.8× 61 0.8× 64 0.9× 32 783
Jian Long China 16 242 1.2× 53 0.3× 63 0.6× 27 0.3× 30 0.4× 46 612
Aihua Fei China 17 165 0.8× 57 0.3× 117 1.2× 129 1.6× 112 1.5× 38 742

Countries citing papers authored by Françoise Brunner‐Ferber

Since Specialization
Citations

This map shows the geographic impact of Françoise Brunner‐Ferber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Brunner‐Ferber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Brunner‐Ferber more than expected).

Fields of papers citing papers by Françoise Brunner‐Ferber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Brunner‐Ferber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Brunner‐Ferber. The network helps show where Françoise Brunner‐Ferber may publish in the future.

Co-authorship network of co-authors of Françoise Brunner‐Ferber

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Brunner‐Ferber. A scholar is included among the top collaborators of Françoise Brunner‐Ferber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Brunner‐Ferber. Françoise Brunner‐Ferber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Audran, R, Haïthem Chtioui, Anne‐Christine Thierry, et al.. (2024). Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study. Scientific Reports. 14(1). 12872–12872. 1 indexed citations
2.
Dao, Kim, Vincent Jullien, Pascal André, et al.. (2022). An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup. Pharmacology Research & Perspectives. 11(1). e01032–e01032. 3 indexed citations
3.
Delden, Christian van, Thilo Köhler, Françoise Brunner‐Ferber, et al.. (2012). Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Medicine. 38(7). 1118–1125. 79 indexed citations
4.
Chavassieux, Pascale, Patrick Garnero, F. Duboeuf, et al.. (2001). Effects of a New Selective Estrogen Receptor Modulator (MDL 103,323) on Cancellous and Cortical Bone in Ovariectomized Ewes: A Biochemical, Histomorphometric, and Densitometric Study. Journal of Bone and Mineral Research. 16(1). 89–96. 69 indexed citations
5.
Buclin, Thierry, et al.. (2000). Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. European Journal of Clinical Pharmacology. 55(10). 749–754. 11 indexed citations
6.
Buclin, Thierry, Jürg Nussberger, Laurent A. Décosterd, et al.. (1999). Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers. Journal of Hypertension. 17(3). 427–437. 29 indexed citations
7.
8.
Gardiner, Sheila M., P.A. Kemp, Françoise Brunner‐Ferber, & T. Bennett. (1997). Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats. British Journal of Pharmacology. 122(8). 1687–1693. 13 indexed citations
9.
Gardiner, Sheila M., P.A. Kemp, Françoise Brunner‐Ferber, & T. Bennett. (1997). Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen‐2)27) rats. British Journal of Pharmacology. 122(8). 1694–1701. 8 indexed citations
10.
Gisclon, L. G., Keith Wesnes, Christopher R. Curtin, et al.. (1996). Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men*. Clinical Pharmacology & Therapeutics. 59(6). 675–685. 6 indexed citations
11.
Willburger, Roland, et al.. (1996). Inhibition of eicosanoid release from synovial organ culture by incubation with tepoxalin and its acid metabolite. Prostaglandins. 52(4). 327–338. 2 indexed citations
12.
Biollaz, Jérôme, Alain Munafo, Thierry Buclin, et al.. (1995). Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. European Journal of Clinical Pharmacology. 47(5). 455–60. 31 indexed citations
13.
Pentikäinen, Pertti J., Markku Saraheimo, Jules I. Schwartz, et al.. (1992). Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans. The Journal of Clinical Pharmacology. 32(2). 136–140. 86 indexed citations
14.
Gunning, Frans P., A Béchetoille, Erik A. Lippa, et al.. (1992). Sezolamide: Additivity to timolol twice daily. Eye. 6(5). 525–529. 4 indexed citations
15.
Brunner‐Ferber, Françoise, et al.. (1992). Assessment of bronchial effects following topical administration of butylamino‐phenoxy‐propanol‐acetate, an oculoselective beta‐ adrenoceptor blocker in asthmatic subjects.. British Journal of Clinical Pharmacology. 34(2). 122–129. 2 indexed citations
16.
Dubertret, Louis, et al.. (1991). Activities of Human Acidic Fibroblast Growth Factor in an In Vitro Dermal Equivalent Model. Journal of Investigative Dermatology. 97(5). 793–798. 19 indexed citations
17.
Bauer, Karin, et al.. (1991). Assessment of systemic effects of different ophthalmic β-blockers in healthy volunteers. Clinical Pharmacology & Therapeutics. 49(6). 658–664. 12 indexed citations
18.
Buclin, Thierry, Jérôme Biollaz, Erik A. Lippa, et al.. (1991). Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clinical Pharmacology & Therapeutics. 49(6). 665–673. 11 indexed citations
19.
Pfeiffer, Norbert, et al.. (1991). Comparative tolerability of topical carbonic anhydrase inhibitor MK-927 and its S-enantiomer MK-417. Graefe s Archive for Clinical and Experimental Ophthalmology. 229(2). 111–114. 5 indexed citations
20.
Brunner‐Ferber, Françoise, et al.. (1990). Ein neuer, lokal anwendbarer Carboanhydrasehemmer (MK-927) - Toleranzvergleich mit Betaxolol bei gesunden Probanden. Klinische Monatsblätter für Augenheilkunde. 197(9). 254–257. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danyal Imani Breakdown of academic impact, for papers by Tetsuro Matsuura Breakdown of academic impact, for papers by Lori Mixson Breakdown of academic impact, for papers by Subhadip Choudhuri Breakdown of academic impact, for papers by Mehmet Namuslu Breakdown of academic impact, for papers by Nedret Kılıç Breakdown of academic impact, for papers by Theo Nell Breakdown of academic impact, for papers by Jian Long Breakdown of academic impact, for papers by Aihua Fei
Rankless by CCL
2026